FDA Approves New Cancer Drug Combo for Kidney Patients

Kidney cancer patients facing the scary possibility of their disease coming back just got a powerful new weapon in their corner.

The FDA approved a new combination treatment pairing pembrolizumab with belzutifan for adults with clear cell renal cell carcinoma, the most common type of kidney cancer. This approval marks the first time these two types of drugs have been combined to prevent cancer from returning after surgery.

The breakthrough came from a major study led by Dr. Toni Choueiri at Dana-Farber Cancer Institute involving 1,841 patients. All had undergone surgery to remove their tumors but faced a high risk of the cancer coming back.

The results were striking. After 24 months, 81% of patients taking the new combination remained cancer-free, compared to 74% receiving the previous standard treatment. That translates to a 28% reduction in the risk of recurrence, metastasis, or death.

"Because surgery alone is not enough for many patients, a meaningful proportion will relapse, often with metastatic disease," Choueiri explained. "This combination provides a more effective strategy to reduce the likelihood of the cancer returning."

The science behind belzutifan is particularly exciting. It blocks a protein called HIF-2α that's overabundant in clear cell kidney cancer and drives tumor growth. The research foundation for this drug earned Dana-Farber's Dr. William Kaelin a Nobel Prize in 2019.

The Ripple Effect

This approval reaches far beyond clinical trials. About 435,000 people worldwide receive kidney cancer diagnoses each year, with clear cell renal cell carcinoma accounting for 75% of cases. Roughly 30% of these patients see their cancer return within five years after surgery, a devastating reality that this new treatment could help prevent.

The approval also includes a subcutaneous version that patients can receive under the skin rather than through IV infusion, making treatment more convenient. Side effects remained consistent with previous studies, meaning doctors already know what to expect and how to manage them.

For patients finishing kidney cancer surgery, knowing their disease might return has been a source of constant worry. Now they have a proven option that significantly improves their odds of staying healthy.